BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26492560)

  • 21. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
    Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study on recombinant humanized anti-CD25 monoclonal antibody used for treating steroid-resistant acute graft versus host disease following allo-hematopoietic stem cell transplantation].
    Li XH; Gao CJ; DA WM; Cao YB; Xu LX; Wu YM; Liu B; Liu ZY; Yan B; Li SW; Yang XL; Wu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1535-40. PubMed ID: 24370044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
    Lu J; Xu LP; Huang XJ; Chen H; Zhang YC; Ren HY; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):216-9. PubMed ID: 12812665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
    Shao S; Liu HX; Jiang Y; Li S; Wei DL; Zhu J; Wang C; Zhao CX
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):115-120. PubMed ID: 38604786
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies.
    Ji SQ; Chen HR; Yan HM; Wang HX; Liu J; Zhu PY; Xiao MH; Xun CQ
    Bone Marrow Transplant; 2005 Aug; 36(4):349-54. PubMed ID: 15968293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation: a preliminary report.
    Zhao T; Yang C; Xue Y; Qiu YY; Hu L; Qiu Y; Wang X; Yang B; Rong R; Xu M; Zhu T
    Transplant Proc; 2012 Jan; 44(1):175-8. PubMed ID: 22310608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation.
    Vondran FW; Timrott K; Tross J; Kollrich S; Schwarz A; Lehner F; Klempnauer J; Becker T; Schwinzer R
    Transpl Int; 2010 May; 23(5):514-23. PubMed ID: 19951265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Humanized anti-CD25 monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation].
    Wu YX; Wu DP; Ma X; Jiang SS; Hou MJ; Jing YT; Liu B; Li Q; Wang X; Wu YB; Hu XH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):755-761. PubMed ID: 38049320
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.
    Schroeder T; Haas R; Kobbe G
    Expert Rev Hematol; 2010 Oct; 3(5):633-51. PubMed ID: 21083479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
    Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab for steroid refractory acute graft-versus-host disease.
    Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
    Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
    Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
    J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
    J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report.
    Piton G; Larosa F; Minello A; Becker MC; Mantion G; Aubin F; Deconinck E; Hillon P; Di Martino V
    Liver Transpl; 2009 Jul; 15(7):682-5. PubMed ID: 19562700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.